Compare CBAN & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBAN | RZLT |
|---|---|---|
| Founded | 1975 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.0M | 187.3M |
| IPO Year | 1998 | N/A |
| Metric | CBAN | RZLT |
|---|---|---|
| Price | $18.25 | $1.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.33 |
| AVG Volume (30 Days) | 87.1K | ★ 12.5M |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | ★ 26.78 | N/A |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $122,550,000.00 | N/A |
| Revenue This Year | $20.97 | N/A |
| Revenue Next Year | $25.65 | N/A |
| P/E Ratio | $11.66 | ★ N/A |
| Revenue Growth | ★ 12.48 | N/A |
| 52 Week Low | $13.99 | $1.07 |
| 52 Week High | $18.80 | $11.46 |
| Indicator | CBAN | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 67.56 | 24.57 |
| Support Level | $18.18 | $1.07 |
| Resistance Level | $18.80 | $2.25 |
| Average True Range (ATR) | 0.40 | 0.60 |
| MACD | 0.07 | -0.77 |
| Stochastic Oscillator | 73.68 | 7.13 |
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.